الفهرس 
MicroRNA expression as a predictor of the success of pegylated interferon-ribavirin therapy against chronic hepatitis C in Egyptian patients
AbstractOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
MicroRNAs (miRNAs) are messengers during interferon (IFN) virus interplay and are involved in antiviral immunity, however, little is known about IFN related miRNAs regarding their detection in serum and their potential use as non invasive diagnostic and prognostic biomarkers in chronic hepatitis C (CHC). Elucidate some of the molecular aspects underlying failure of pegylated IFN (PegIFN)-Ü/ribavirin (RBV) combination therapy, the present study investigated pretreatment expression profiles of seven selected IFN related miRNAs (miR- 146a, miR-34a, miR-130a, miR-19a, miR-192, miR-195, and miR-296) by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) custom array technology in serum of Egyptian CHC patients with genotype 4 and whether their pretreatment levels would predict patient response to the combination therapy. One hundred and six CHC patients and forty age and sex- matched healthy controls were included. CHC patients were treated with standard PegIFN-Ü2b / RBV therapy and according to the virological response; they were divided into sustained virological response (SVR) and non-responder (NR) groups. Serum miR-34a, miR-130a, miR-19a, miR-192, miR-195, and miR-296 were upregulated, whereas serum miR-146a was downregulated in CHC patients compared to healthy controls. Significant correlations were found between relative expression levels of studied miRNAs and also with clinical data in CHC group. Pretreatment levels of serum miR-34a, miR-130a, and miR-195 were significantly higher, whereas miR-192 and miR-296 levels were significantly lower in SVR than NR patients